Continuous manufacturing is reshaping biologics - and today’s guest is one of the leaders driving that shift.

This week, in another episode of the Making It in Manufacturing Spotlight Series, we sit down with Himanshu Gadgil, PhD, CEO of Enzene. With over a decade of experience spanning scientific innovation, biologics development & manufacturing, global expansion and CDMO leadership, Himanshu shares the story behind Enzene’s rise from a small R&D biotech in India to a rapidly scaling global CIDMO with newly established US manufacturing.

In this episode, Himanshu covers:

- How Enzene built and evolved its first-in-class, fully-connected continuous manufacturing platform, EnzeneX - including initial failures shaped breakthrough innovation.

- Why fully-connected continuous manufacturing™ is a cost and efficiency game-changer for biologics.

- The regulatory and operational challenges of scaling this technology - and how Enzene approached India-to-US expansion.

- Leadership lessons in his progression from scientist to CEO, including culture, resilience, and recognising that success depends on the combination of transformative innovation with a unique values/mission-driven approach to the way business gets done.

- The future of biomanufacturing - from localisation and personalised production to fully automated, analytics-driven systems.

Be sure to check out this episode to hear how Enzene is redefining what a modern CDMO can be.

To listen to (or watch) the full episode, search "Making it in Manufacturing Enzene" on your preferred streaming platform, or click on the first link in the comments below.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com

Youtube: https://www.youtube.com/@life_sciences

Himanshu Gadgil

CEO of Enzene

LinkedIn: https://www.linkedin.com/in/himanshu-gadgil-3326307/

Thomas McMann

Director - Contracts Division

LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/

Timestamps:

00:10 Enzene's Vision

04:10 Building & Scaling a Global Platform

07:51 Enzene's Competitive Edge

14:56 The Future of CDMO's

21:01 Vision for Enzene's Future Growth

Hosted on Acast. See acast.com/privacy for more information.

The CDMO everyone’s suddenly talking about, and the CEO taking it to the next level.

This week, in another episode of the Making It in Manufacturing Spotlight Series, hosted by Thomas McMann, we sit down with Dirk T. Lange, CEO at Pyramid Pharma Services. With 30 years of experience across drug-substance and drug-product CDMOs, global operations, outsourcing leadership, and life-science services, spanning Rentschler, KBI Biopharma, Novartis, Sandoz, and more, Dirk brings a rare dual-lens perspective from both the provider and sponsor side.

In this episode, Dirk covers:

- A full overview of Pyramid Pharma Services, a 37-year-old CDMO with an exceptionally broad drug-product offering from clinical to commercial supply.

- Key data behind Pyramid’s under-the-radar growth, including 15 successful FDA inspections, a strong legacy of quality, and decades of organic expansion driven by long-term customer partnerships.

- Why they’re doubling their fill–finish capabilities, including the strategic drivers, client demand, and the transition from clinical-scale to high-speed commercial lines.

- The operational realities of scaling, from maintaining culture to onboarding new teams, strengthening processes, and preserving execution excellence during rapid growth.

- How Pyramid positions itself as an enabler in the supply chain, supporting customers from early development through long-term commercial supply.

Be sure to check out this episode, a deep dive into what it really takes to scale a legacy CDMO while protecting quality, culture, and customer trust.

To listen to (or watch) the full episode, search "Making it in Manufacturing Pyramid Pharma" on your preferred streaming platform, or click on the first link in the comments below.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com

Youtube: https://www.youtube.com/@life_sciences

Dirk T. Lange

CEO at Pyramid Pharma Services

LinkedIn: https://www.linkedin.com/in/langedirk/

Thomas McMann

Director - Contracts Division

LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/

Timestamps:

00:11 Pyramid Overview

01:41 Key Data

03:46 Doubling Fill Finish Capabilities

05:38 Growth Challenges

Hosted on Acast. See acast.com/privacy for more information.

In this episode of the Making It in Manufacturing Spotlight Series, we sit down with Raj Puri, Chief Commercial Officer at Argonaut Manufacturing Services.

With over 12 months in the CCO role and extensive experience across the CDMO space, Raj brings insight from leading business development, project management, and commercial strategy across both life science/diagnostics and aseptic drug-product services.

In this episode, Raj covers:

- Why Argonaut chooses to support “N of 1” programmes, and the cultural impact of delivering life-saving therapies for single-patient treatments.

- The operational challenges of ultra-high-value API filling, and how Argonaut minimises line losses for rare-disease therapies.

- The company’s evolution, from diagnostics to becoming a major player in small- to mid-scale aseptic drug-product manufacturing.

- How Argonaut’s new $45M facility and commercial-scale filling line will transform output, enable prefilled syringes/cartridges, and support global demand.

- The realities of scaling a CDMO, including hiring, maintaining culture, preparing for FDA pre-approval inspection, and setting long-term strategy for future capabilities.

Be sure to check out this episode to hear Raj’s candid take on growth, culture, and the future of drug-product manufacturing.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com

Youtube: https://www.youtube.com/@life_sciences

Raj Puri

CCO at Argonaut Manufacturing Services

LinkedIn: https://www.linkedin.com/in/raj-puri-3137665/

Thomas McMann

Director - Contracts Division at ARTO

LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/

Timestamps:

00:10 Stepping Into The Role & Early Lessons

04:03 Scaling Smart: Challenges and Capabilities

09:07 Culture, Talent & The Future

Hosted on Acast. See acast.com/privacy for more information.